Search results for "Coma"

showing 10 items of 1084 documents

Reconstruction of full thickness scalp defects after tumour excision in elderly patients: our experience with Integra dermal regeneration template.

2010

Summary Background Scalp reconstruction after wide tumor excision is particularly challenging. Free tissue transfers, local flaps, or skin grafts can be used but present some disadvantages especially with old patients with local advanced cancers, systemic diseases and in patients with a prior history of recurring scalp skin cancers in which the risk of burying a recurring tumor with a flap is likely. The Authors expose their early experience with Integra ® dermal regeneration template for scalp reconstruction after scalp tumor excision. Methods Eight patients with primary or secondary scalp tumor underwent a first surgical procedure under local anaesthesia for tumor removal and Integra ® po…

Integra tumor scalp scalp defectmedicine.medical_specialtySkin NeoplasmsSettore MED/19 - Chirurgia PlasticaTumor excisionScalp reconstructionmedicineHumansMelanomaTumour excisionAged 80 and overSkin ArtificialScalpintegumentary systembusiness.industryRegeneration (biology)Chondroitin SulfatesSarcomaPlastic Surgery ProceduresSurgeryTumor recurrenceSkullmedicine.anatomical_structureScalpCarcinoma Squamous CellWounds and InjuriesSurgeryFull thicknessCollagenbusinessJournal of plastic, reconstructiveaesthetic surgery : JPRAS
researchProduct

The Fibril-associated Collagen IX Provides a Novel Mechanism for Cell Adhesion to Cartilaginous Matrix

2004

Collagen IX is the prototype fibril-associated collagen with interruptions in triple helix. In human cartilage it covers collagen fibrils, but its putative cellular receptors have been unknown. The reverse transcription-PCR analysis of human fetal tissues suggested that based on their distribution all four collagen receptor integrins, namely alpha1beta1, alpha2beta1, alpha10beta1, and alpha11beta1, are possible receptors for collagen IX. Furthermore primary chondrocytes and chondrosarcoma cells express the four integrins simultaneously. Chondrosarcoma cells, as well as Chinese hamster ovary cells transfected to express alpha1beta1, alpha2beta1, or alpha10beta1 integrin as their only collage…

Integrin alpha1Integrin alpha2LigandsPolymerase Chain ReactionBiochemistryCollagen receptorMiceCricetinaeReceptorbiologyReverse Transcriptase Polymerase Chain ReactionChemistryChinese hamster ovary cellRecombinant ProteinsCell biologyBiochemistryCollagenIntegrin alpha ChainsProtein BindingMolecular Sequence DataIntegrinChondrosarcomaCHO CellsFibrilCollagen Type IXCell LineChondrocytesMicroscopy Electron TransmissionCell Line TumorCell AdhesionEscherichia coliAnimalsHumansImmunoprecipitationAmino Acid SequenceRNA MessengerBinding siteCell adhesionMolecular BiologyBinding SitesSequence Homology Amino AcidCell BiologyProtein Structure TertiaryRatsMicroscopy ElectronCollagen type I alpha 1CartilageMutationMutagenesis Site-Directedbiology.proteinRNAPeptidesJournal of Biological Chemistry
researchProduct

Transcription of α2 Integrin Gene in Osteosarcoma Cells Is Enhanced by Tumor Promoters

1998

Integrin alpha2beta1 is a heterodimeric transmembrane receptor for collagens. In osteogenic cells the expression of alpha2beta1 integrin is induced by both Kirsten sarcoma virus and chemical transformation. The association of alpha2 integrin with transformed cell phenotype was studied further by testing the effects of two tumor promoters, 12-O-tetradecanoylphorbol 13-acetate (TPA) and okadaic acid (OA), on human MG-63 osteosarcoma cells. TPA, an activator of protein kinase C, increased the cell surface expression of alpha2 integrin and the corresponding mRNA levels. Nuclear run-on assays indicated that TPA activated the transcription of alpha2 integrin gene. TPA also slightly increased the …

IntegrinsTime FactorsTranscription GeneticIntegrin alpha3IntegrinIntegrin alpha2CD18Integrin alpha5CD49cCD49bCollagen receptorAntigens CDOkadaic AcidCell AdhesionTumor Cells CulturedHumansCollagenasesRNA MessengerOsteosarcomabiologyActivator (genetics)Integrin beta1Cell BiologyIntegrin alphaVBlotting NorthernFlow CytometryMolecular biologyUp-RegulationIntegrin alpha MCarcinogensbiology.proteinTetradecanoylphorbol AcetateIntegrin beta 6CollagenMatrix Metalloproteinase 1Experimental Cell Research
researchProduct

Depletion of alphaV integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses g…

1999

Integrin heterodimers sharing the common alphaV subunit are receptors for adhesion glycoproteins such as vitronectin and fibronectin. They are suggested to play an essential role in cell anchoring, differentiation, and survival. Here, we describe the construction of an expression plasmid coding for an intracellular single-chain antibody against alphaV integrin subunit. Saos-2 osteosarcoma cells transfected with this DNA construct showed an approximately 70-100% decrease in the cell surface expression of alphaVbeta3 and alphaVbeta5 integrins as shown by flow cytometry. Intracellular antibody expression had no effect on the mRNA levels of alphaV integrin. Pulse chase experiments of metabolica…

Intracellular FluidSialoglycoproteinsCellIntegrinBone and Bones03 medical and health sciences0302 clinical medicineAntigens CDmedicineCell AdhesionTumor Cells CulturedHumansOsteopontinVitronectinMolecular BiologyImmunoglobulin Fragments030304 developmental biologyGlycoproteins0303 health sciencesOsteosarcomabiologyOsteoblastCell DifferentiationTransfectionIntegrin alphaVAlkaline PhosphataseMolecular biologyFibronectinsFibronectinmedicine.anatomical_structure030220 oncology & carcinogenesisEnzyme Inductionbiology.proteinMatrix Metalloproteinase 2VitronectinOsteopontinIntracellularBiomarkersMatrix biology : journal of the International Society for Matrix Biology
researchProduct

miRNAs and Genes Involved in the Interplay between Ocular Hypertension and Primary Open-Angle Glaucoma. Oxidative Stress, Inflammation, and Apoptosis…

2021

Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2077-0383/10/11/2227 En esta investigación también participan: Mar Valero Vello, Silvia M. Sanz González, José E. O'Connor, David Galarreta Mira, María D. Pinazo-Durán y Vicente Zanón Moreno. Este artículo pertenece al número especial "Recent Clinical Research on Glaucoma". Glaucoma has no cure and is a sight-threatening neurodegenerative disease affecting more than 100 million people worldwide, with primary open angle glaucoma (POAG) being the most globally prevalent glaucoma clinical type. Regulation of gene expression and gene networks, and its multifactorial pathways involved in glaucoma disease are landmark…

Intraocular pressureBiochemical markers.Open angle glaucomagenetic structuresGlaucomaOcular hypertensionDiseaseBioinformaticsArticle03 medical and health sciences0302 clinical medicineGene expressionmicroRNAApoptosis.Medicineoxidative stressGlaucoma.genes030304 developmental biologyRegulation of gene expressionEstrés oxidativo.next generation sequencing0303 health sciencesbusiness.industryPresión intraocular.apoptosisneurodegenerationIntraocular pressure.RMarcadores bioquímicos.tearsbiomarkersGeneral Medicinemedicine.diseasesignaling pathwayseye diseasesOxidative stress.glaucomainflammationmiRNAs030221 ophthalmology & optometryocular hypertensionMedicinebusinessJournal of Clinical Medicine
researchProduct

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

2002

Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy …

Intraocular pressureMydriaticsgenetic structuresCombination therapymedicine.medical_treatmentAdrenergic beta-AntagonistsTimololGlaucomachemistry.chemical_compoundMedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureChemotherapyDipivefrinbusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmologyProstaglandin analogchemistryAnesthesiaProstaglandins F SyntheticLatanoprostDrug Therapy CombinationOcular Hypertensionsense organsOphthalmic SolutionsSafetybusinessmedicine.drugSurvey of ophthalmology
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Tonographic Effect of Ocular Response Analyzer in Comparison to Goldmann Applanation Tonometry.

2016

AIMS The tonographic effect is a phenomenon of intraocular pressure (IOP) reduction following repeated tonometry. This study examines whether the tonographic effect occurs following IOP measurement performed with Ocular Response Analyzer (ORA). METHODS Both eyes of 31 glaucoma patients and 35 healthy controls underwent nine IOP-measurements performed with GAT and ORA. The number of GAT and ORA measurements performed on each eye differed depending on the randomly allocated investigation scheme. Central corneal thickness (CCT), anterior chamber volume (ACV) and anterior chamber depth (ACD) were assessed with Pentacam before and after the repeated GAT/ORA measurements. RESULTS There was no sta…

Intraocular pressuregenetic structuresEye DiseasesPhysiologyGlaucomalcsh:MedicineWalkingGoldmann applanation tonometryCornea0302 clinical medicineMedicine and Health SciencesMedicineBiomechanicslcsh:ScienceMultidisciplinaryOphthalmic ProceduresDrugsMiddle AgedFemaleAnatomyResearch ArticleAdultmedicine.medical_specialtyOcular AnatomySurgical and Invasive Medical ProceduresCorneal hysteresis03 medical and health sciencesTonometry OcularOcular SystemOphthalmologyHumansPain ManagementIn patientIntraocular PressureAgedAnestheticsPharmacologybusiness.industryBiological Locomotionlcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesOphthalmologyCase-Control Studies030221 ophthalmology & optometryEyeslcsh:Qsense organsbusinessHead030217 neurology & neurosurgeryPloS one
researchProduct

2021

Muscarinic acetylcholine receptors (mAChRs) belong to the superfamily of G-protein-coupled receptors (GPCRs). The family of mAChRs is composed of five subtypes, M1, M2, M3, M4 and M5, which have distinct expression patterns and functions. In the eye and its adnexa, mAChRs are widely expressed and exert multiple functions, such as modulation of tear secretion, regulation of pupil size, modulation of intraocular pressure, participation in cell-to-cell signaling and modula-tion of vascular diameter in the retina. Due to this variety of functions, it is reasonable to assume that abnormalities in mAChR signaling may contribute to the development of various ocular diseases. On the other hand, mAC…

Intraocular pressuregenetic structuresGlaucomaCatalysisInorganic Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMuscarinic acetylcholine receptormedicineTear secretionPhysical and Theoretical ChemistryReceptorMolecular BiologySpectroscopyG protein-coupled receptorRetinabusiness.industryOrganic ChemistryRetinalGeneral Medicinemedicine.diseaseeye diseasesComputer Science Applicationsmedicine.anatomical_structurechemistry030221 ophthalmology & optometrysense organsbusinessNeuroscience030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

2014

Lowering intraocular pressure (IOP) is at present the only therapeutic approach to the treatment of glaucoma proven to be successful. The choice of therapy must take into account efficacy, tolerability, safety, quality of life, adherence and cost. Monotherapy fails to achieve a satisfactory IOP reduction in 40 - 75% of glaucoma patients after2 years of therapy. So far, three prostaglandin/timolol maleate 0.5% fixed combinations (FCs) are available.This review provides a background on the tafluprost-timolol FC (TTFC, Santen Oy) and its individual compounds. It summarizes the data on efficacy and safety, including comparative data with prostaglandin/timolol FCs already available.Tafluprost is…

Intraocular pressuregenetic structuresOpen angle glaucomaDrug-Related Side Effects and Adverse ReactionsOcular hypertensionTimololGlaucomamedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologybusiness.industryProstaglandins FTafluprostGlaucomaGeneral Medicinemedicine.diseaseeye diseasesDrug CombinationsProstaglandin analogTolerabilityAnesthesiaTimololDrug Evaluationlipids (amino acids peptides and proteins)Ocular Hypertensionsense organsbusinessGlaucoma Open-Anglemedicine.drugExpert opinion on pharmacotherapy
researchProduct